If a stock makes a recovery after having gone through a period of recording losses consistently, then it may be a good time to start tracking that stock. After all, if the recovery persists then investors could end up making significant returns. A stock that made a semblance of recovery on Thursday was of BioAdaptives Inc (OTCMKTS:BDPT), which ended the day with gains of as much as 3%. While the recovery may be important, it ought to be noted that for the past week, the stock is still down by as much as 20%. It is now going to be interesting to see if the BioAdaptives stock can hold on to this momentum and manage to claw back more of the losses.
In order to figure out if this could be an opportunity, it is important for investors to get a better idea about BioAdaptives as a company and then check out the latest news.
Trading Data
On Thursday, BDPT stock moved up 3% to $0.0036 with more than 2.67 million shares, compared to its average volume of 912K shares. The stock moved within a range of $0.0035 – 0.0043 after opening trade at $0.0040.
About BioAdaptives
The company is involved in the manufacturing and distribution of plant and algae-based products that are focused on health and wellness. BioAdaptives makes these products for both human beings and animals.
The products are mainly meant for anti-viral activity, pain relief, stress resistance, immunity, aiding recovery from injuries, and anti-aging among others. The common shares of the company are listed on the OTC Market and it trades under the ticker symbol BDPT. It should however be noted that none of the products that are distributed by BioAdaptives are actually approved by the United States Food and Drug Administration.
BioAdaptives, Inc. Introduces PrimiSleep
As it happens, the company was actually in the news yesterday and it is now time to take a look into it since it had led to the recovery in the BioAdaptives stock. The company announced yesterday that it had launched a new product named PrimeSleep, which is a fully natural product meant for tackling stress. It is particularly aimed at bringing about relaxation and thereby helping people in experiencing continuous, restful sleep.
The company claimed that the product had been test-marketed rigorously and developed with considerable diligence. It is an advanced level formulation and was formulated through the knowledge available in Ayurveda and Traditional Chinese Medicine. At this point in time, there is an increasing demand for natural products which could help with sleep and not induce the ‘hangover effect’ that is common with traditional sleeping pills.
In addition to that, it is also necessary to point out that PrimeSleep has been developed in such a way that there is not going to be any change in the cognitive capabilities of an individual. That is an effect that is quite common with pharmaceutical sleeping pills. The launch of a new product is almost always a significant one for any company and when the product is a potentially popular one, then the excitement among investors is understandable. It is going to be interesting to see if investors continue to flock to the BioAdaptives stock this morning or not.
Key Quote
Edward Jacobs, M.D., BioAdaptives’ CEO, states, “The average adult needs about 7- 8 hours of sleep per day to remain healthy and productive. The striking rise in sleep-related challenges may be due to a variety of factors from coping with more stressful lifestyles in general, to perhaps even the emergence of new, chronic such as “Long Haul” symptoms experienced after COVID 19 infections. We are pleased to meet the rising demand of those seeking help to manage sleep disturbance by offering the clinically supported all-natural supplement, PrimiSleep™.”
Technical Data
BDPT stock is trading below the 20-Day and 50-Day Moving averages of $0.0047 and $0.0051 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0117. The company has a total market capitalization of 241K with 67.37 million outstanding shares. Moreover, the company has 82.38% or 55.5 million floating shares. The stock is down 30% over the past month.
